Benchmark Maintains Speculative Buy on Humacyte, Lowers Price Target to $1

Benzinga · 1d ago
Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and lowers the price target from $2 to $1.